SPECIAL NOTICE
66 -- T-Spot Tuberculosis (TB) Lab Testing
- Notice Date
- 8/4/2013
- Notice Type
- Special Notice
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- PR62790
- Archive Date
- 9/2/2013
- Point of Contact
- Arnette L. Mayhew, Phone: 7704882883, Teri Routh-Murphy, Phone: 7704882713
- E-Mail Address
-
hrb5@cdc.gov, tnr3@cdc.gov
(hrb5@cdc.gov, tnr3@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- NOTICE OF INTENT TO SOLE SOURCE: The Centers for Disease Control and Prevention (CDC) announces its intention to negotiate a sole source award with the Oxford Immunotec, Marlborough, MA. CDC has an on-going study to compare the Tuberculin skin testing (TST) to Interferon-gamma release assays (IGRA). The Tuberculosis Elimination Study Constortium (TBESC)'s two main study objectives are to evaluate and compare the performance of TSTs and IGRAs in (1) diagnosing latent TB Infection (LTBI); and, (2) predicting progression from LTBI to TB Disease including subgroups of patients. As part of this study, different IGRAs will be employed. Both QuantiFERON® TB Gold In-Tube (QFT-G In-Tube) as well as T-SPOT TB. The purpose of this requirement is to add 6,604 T-SPOT TB tests Tests to the current Contract 200-2012-52749 for the remaining six (6) option period of 12 months each. The period of performance for this contract: September 29, 2012 - September 28, 2019. Oxford Immunotec is the sole proprietor of the T-SPOT TB and is also FDA Approved. Therefore, CDC intends to negotiate this requirement with Oxford Immunotec under the authority of FAR 6.302-1 and HHSAR 306.302-1, Only One Responsible Source, and 41 U.S.C. 253(c)(1). This notice of intent is not a request for competitive proposals. A determination to compete this procurement based on a response to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement should submit a capability statement demonstrating their abilities to meet this requirement. All responses should be received by the August 18, 2013, at 8 AM, Eastern Standard Time (EST). All responses must be in writing and can be sent via email to hrb5@cdc.gov or faxed to 770-488-2868. No phone calls will be accepted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/PR62790/listing.html)
- Place of Performance
- Address: At the contractor's facility, Malborough, Massachusetts, United States
- Record
- SN03137049-W 20130806/130804233028-e5494a53b5b64d0825c7b7483a182c42 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |